FDA to review Schering-Plough schizophrenia tablet
November 26, 2007
Drug developer Schering-Plough Corp. is seeking marketing approval from the Food and Drug Administration for a tablet used to treat schizophrenia and bipolar disorder, the Associated Press reports. Schering-Plough said the FDA accepted the new drug application of asenapine for a standard review. Schering-Plough acquired asenapine through its buyout of Organon BioSciences NV earlier this month. The clinical trial program for the drug has so far consisted of schizophrenia.